US EditionPublished • loading... • Updated
Weight-loss wonder: CNS still reimburses Ozempic only for diabetes as semaglutide prescriptions rise
Summary by rtl.lu
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Weight-loss wonder: CNS still reimburses Ozempic only for diabetes as semaglutide prescriptions rise
Luxembourg's Health Ministry says Ozempic and Rybelsus remain reimbursed only for type-2 diabetes patients, while it keeps the door open to possible future coverage of obesity treatments after the WHO’s new guidance, as CNS data shows prescriptions for semaglutide drugs continuing to rise.
·Luxembourg City, Luxembourg
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
